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Background
Fas/Fas ligand (FasL)-dependent apoptotic pathway was
reported to be involved in the pathogenesis of drug
induced maculopapular rashes (MPRs). In this study, we
investigated serum soluble FasL level to discriminate
drug-induced skin reactions from other clinically resem-
bling skin diseases such as exanthematous viral infec-
tions. We also eveluated the role of T cells in various
drug-induced diseases.
Methods
We analyzed 7 patients with drug induced MPRs (group
I), 17 patients with viral exanthemas (group II), 6 paients
with DRESS [grup III], and 15 healthy children with no
history of adverse drug reactions. A complete blood count
and immunophenotyping of peripheral blood lymphocytes
were carried out, as well serum FasL levels were analyzed
in group I-III (Human sFas-L ELISA kit, eBioscience,
Vienna, Austria), within 2 days after the onset of the skin
eruptions. Tests were repeated between days 3-5 and days
6-10. In group IV, these analyses were performed once.
Liver and renal functions were also eveluated in group I-
III. Serum immunoglobulin levels were analyzed in group
3. Skin tests with the suspected drug were applied in cases
in group I and III according to the guidelines. In group II,
skin tests, drug provocation tests, and viral serology were
performed if needed.
Results
Absolute numbers of peripheral blood lymphocytes ans
sFasL levels in initial samples of cases in 4 groups are
summarized in Table 1.
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Table 1
Group 1 Group 2 Group 3 Group 4
sFasL (ng/ml) Mean±SD 0.20±0.14 0.24±0.16 0.22±0.16 0.19±0.21
Median 0.27 0.20 0.18 0.10
CD3+/CD4+ cells* Mean±SD 1508±1230 1761±824 918±552 1240±347
Median 1026 1604 741 1212
CD3+/CD8+ cells* Mean±SD 1735±1839 888±463 509±355 723±252
Median 1376 910 407 624
CD19+ cells* Mean±SD 622±322 1049±659 195±181 535±286
Median 630 834 132 489
CD3)/CD16+/CD56+(NK cells)* Mean±SD 151-980 264-3009 20-487 103-1241
Median 250±238 181±111 94±34 253±235
*Counts, cells/ml
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B cell counts were low in group III when compared to
group I and IV. CD4+cells, CD19+cells and NK cells
were low in group III when compared to group II.
There were no significant differences in sFasL levels
between the groups.
Conclusions
In our study, sFasL levels were not found to be useful to
discriminate viral exanthemas from drug rashes. Addi-
tionally, the results were not found to be different on
repeated evaluations. The only significant difference
between drug induced MPRs and DRESS was B cell
counts. The low numbers of B cells in DRESS within
the first 2 days of the symptoms might be a useful pre-
dictor of DRESS development.
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